1. Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038). (February 2017) Authors: Sadeghi, S.; Groshen, S.; Parikh, R.; Mortazavi, A.; Dorff, T.; Hoimes, C.; Pal, S.; Levine, E.; Doyle, L.; Quinn, D.; Newman, E.; Lara, P. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2539 A phase II trial of AEZS-108 in castration and taxane resistant prostate cancer. (September 2015) Authors: Pinski, J.; Schally, A.V.; Groshen, S.; Denice, T.W.; Liu, S.V.; Quinn, D.; Dorff, T.; Athreya, K.; Yu, S.; Xiong, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S488 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). (December 2016) Authors: El-Khoueiry, A.; Gitlitz, B.; Cole, S.; Tsao-Wei, D.; Goldkorn, A.; Quinn, D.; Lenz, H.J.; Nieva, J.; Dorff, T.; Oswald, M.; Berg, J.; Menendez, X.; Karakozian, K.; Krasnoperov, V.; Liu, R.; Thomas, J.; Groshen, S.; Gill, P. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗